These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 35353553)
1. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. Parsons DW; Janeway KA; Patton DR; Winter CL; Coffey B; Williams PM; Roy-Chowdhuri S; Tsongalis GJ; Routbort M; Ramirez NC; Saguilig L; Piao J; Alonzo TA; Berg SL; Fox E; Hawkins DS; Abrams JS; Mooney M; Takebe N; Tricoli JV; Seibel NL; J Clin Oncol; 2022 Jul; 40(20):2224-2234. PubMed ID: 35353553 [TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. Vo KT; Sabnis AJ; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Jaju A; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW JCO Precis Oncol; 2024 Jun; 8():e2400103. PubMed ID: 38935895 [TBL] [Abstract][Full Text] [Related]
3. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). Macy ME; Mody R; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Williams PM; Patton DR; Coffey BD; Roy-Chowdhuri S; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW JCO Precis Oncol; 2024 Sep; 8():e2400418. PubMed ID: 39298716 [TBL] [Abstract][Full Text] [Related]
4. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA; J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619 [TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. Eckstein OS; Allen CE; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga J; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW J Clin Oncol; 2022 Jul; 40(20):2235-2245. PubMed ID: 35363510 [TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. Laetsch TW; Ludwig K; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Mhlanga J; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW JCO Precis Oncol; 2024 Sep; 8():e2400258. PubMed ID: 39298693 [TBL] [Abstract][Full Text] [Related]
7. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094 [TBL] [Abstract][Full Text] [Related]
8. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Glade Bender JL; Pinkney K; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW Oncologist; 2024 Jul; 29(7):638-e952. PubMed ID: 38815151 [TBL] [Abstract][Full Text] [Related]
9. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors. Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416 [TBL] [Abstract][Full Text] [Related]
10. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. Allen CE; Laetsch TW; Mody R; Irwin MS; Lim MS; Adamson PC; Seibel NL; Parsons DW; Cho YJ; Janeway K; J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28376230 [TBL] [Abstract][Full Text] [Related]
11. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA; J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567 [TBL] [Abstract][Full Text] [Related]
13. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Aplenc R; Fisher BT; Huang YS; Li Y; Alonzo TA; Gerbing RB; Hall M; Bertoch D; Keren R; Seif AE; Sung L; Adamson PC; Gamis A Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2(Suppl 2):37-43. PubMed ID: 22552978 [TBL] [Abstract][Full Text] [Related]
14. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Chang W; Brohl AS; Patidar R; Sindiri S; Shern JF; Wei JS; Song YK; Yohe ME; Gryder B; Zhang S; Calzone KA; Shivaprasad N; Wen X; Badgett TC; Miettinen M; Hartman KR; League-Pascual JC; Trahair TN; Widemann BC; Merchant MS; Kaplan RN; Lin JC; Khan J Clin Cancer Res; 2016 Aug; 22(15):3810-20. PubMed ID: 26994145 [TBL] [Abstract][Full Text] [Related]
15. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441 [No Abstract] [Full Text] [Related]
16. Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. Faulk KE; Anderson-Mellies A; Cockburn M; Green AL PLoS One; 2020; 15(4):e0230824. PubMed ID: 32324751 [TBL] [Abstract][Full Text] [Related]
18. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. Mody RJ; Wu YM; Lonigro RJ; Cao X; Roychowdhury S; Vats P; Frank KM; Prensner JR; Asangani I; Palanisamy N; Dillman JR; Rabah RM; Kunju LP; Everett J; Raymond VM; Ning Y; Su F; Wang R; Stoffel EM; Innis JW; Roberts JS; Robertson PL; Yanik G; Chamdin A; Connelly JA; Choi S; Harris AC; Kitko C; Rao RJ; Levine JE; Castle VP; Hutchinson RJ; Talpaz M; Robinson DR; Chinnaiyan AM JAMA; 2015 Sep; 314(9):913-25. PubMed ID: 26325560 [TBL] [Abstract][Full Text] [Related]
19. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project. Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973 [TBL] [Abstract][Full Text] [Related]
20. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Coyne GO; Takebe N; Chen AP Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]